-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For patients with advanced Parkinson's disease, the drug levodopa becomes less effective in relieving symptoms due to the inevitable loss of dopamine-releasing neurons
Levodopa (levodopa) is one of the most commonly used drugs in the treatment of Parkinson's disease
Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra
In the same study, they also explained why dopaminergic neurons disappear
This study on mice was published in the journal Nature on November 3, and it is expected to discover Parkinson's disease patients five years in advance, develop therapies to slow the progression of the disease, and treat patients with advanced disease
The loss of functional mitochondrial complex I in substantia nigra dopaminergic neurons is a hallmark of Parkinson's disease
They found that the destruction of the energy factories (the mitochondria) in dopaminergic neurons is enough to cause Parkinson's disease
Corresponding author D.
"For a long time, people have been arguing whether mitochondrial damage is the cause or consequence of the disease
Researchers proved that a gene therapy targeting the substantia nigra effectively improves the effect of levodopa
Surmeier said: "This new model can help us develop tests to identify those who may be suffering from Parkinson's disease in the next 5 to 10 years
Original Search
González-Rodríguez, P.